



nContact Launches New International Corporate Website **www.ncontactsurgical.eu**

Morrisville, NC – January 8, 2010 - nContact Surgical, Inc. (“nContact”), a leader in the development of coagulation devices that enable the minimally-invasive treatment of atrial fibrillation (AF), announced today the launch of its new international corporate website, www.ncontactsurgical.eu. The new website is a detailed technology reference source that explains how nContact has utilized its technology and experiences to reach new markets.

The site was designed with a new look to reflect nContact’s success in the treatment of all patients with AF using its *Numeris® Guided Coagulation System with VisiTrax®*, the coagulation device utilized in the convergent procedure, a closed chest AF treatment procedure. In addition to other relevant topics, website visitors will be able to view the latest information on nContact’s coagulation device, its applied *VisiTrax®* technology, and the convergent procedure, including detailed images and animation videos.

“We are excited about this new educational tool and to be able to share the success of the convergent procedure,” said John P. Funkhouser, President and CEO of nContact. “The website offers the opportunity to further educate visitors about AF, the benefits of the convergent procedure, and how this procedure combines techniques of Cardiovascular Surgeons and Electrophysiologists in a single procedure.”

About nContact Surgical, Inc.

nContact is a medical device company founded in 2005 with the company mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The *Numeris® Coagulation System with VisiTrax®* is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, bi-atrial epicardial lesions on a beating heart.

To date, The *Numeris Coagulation System with VisiTrax* is indicated for the coagulation of cardiac tissue in the United States. nContact has initiated clinical studies for the treatment of AF in both open and closed chest procedures. The *Numeris Coagulation System with VisiTrax* has CE Mark approval in Europe for the specific indication for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.

nContact, Inc.
1001 Aviation Parkway, Ste 400
Morrisville, NC 27560
T (919) 466-9810
F (919) 466-9811

Media Contacts

Angela Moser
nContact Surgical, Inc.
amoser@ncontactsurgical.com

Scott Lerman
The Ruth Group
T (646) 536-7013
slerman@theruthgroup.com